Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Consensus Recommendation of “Moderate Buy” by Analysts
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month […]
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month […]
